RecruitingNCT05504681

Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic

Sponsor

Baptist Health South Florida

Enrollment

200 participants

Start Date

Nov 30, 2021

Study Type

OBSERVATIONAL

Conditions

Neurocognitive Disorders

Summary

This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

All adult (18+) patients with central nervous system (CNS) tumors, both primary brain malignancies and brain metastases, treated with radiotherapy (partial brain, stereotactic radiosurgery, stereotactic fractionated radiotherapy, or whole-brain radiotherapy), surgery, and/or antineoplastic therapy and followed thereafter at Miami Cancer Institute (MCI)
Life expectancy ≥ 6 months
Willingness to participate in ongoing registration study

Exclusion Criteria2

Patients receiving radiotherapy to the brain for functional disease (arteriovenous malformations, trigeminal neuralgia, essential tremors, etc.)
Pediatric patients (<18 years old), pregnant women, and prisoners.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservational study

It takes the patient on average 15 minutes to complete the Brainlab Cognition app.

Locations(1)

Miami Cancer Institute

Miami, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05504681

Related Trials

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

NCT057418533 locations

Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders

NCT072050031 location